IntraBio Media Release | February 7, 2024
- ANPDF
- Feb 8, 2024
- 1 min read
The New England Journal of Medicine has published a "Science behind the study" editorial on IB1001
Read the full announcement from IntraBio here:
We are pleased to share that The New England Journal of Medicine (NEJM) has published a "Science Behind the Study” Expert Perspective Editorial on N-acetyl-L-leucine (IB1001) for the treatment of neurodegenerative diseases:
The Editorial reports the broad potential of IB1001 as a treatment of neurodegenerative diseases and recognises the applicability of IB1001 for the treatment of various neurodegenerative disorders, including all neurodegenerative lysosomal storage diseases, heritable cerebellar ataxias, and common disorders like traumatic brain injury.
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia:
Check out upcoming events
Shop at our online NPC store
Fundraise your way! Check our free resources and inspo online.
Comments